Diagnostic Model of in-Hospital Mortality in Patients with Acute ST-Segment Elevation Myocardial Infarction: Algorithm Development and Validation

Yong Li, MSc

Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Corresponding Author:Yong Li, MSc Emergency and Critical Care Center Beijing Anzhen Hospital Capital Medical University. Email: liyongdoctor@sina.com.

Abstract

Background: Coronary heart disease, including ST-segment elevation myocardial infarction (STEMI), remains the main cause of death.

Objectives: The objective of our research was to develop and externally validate a diagnostic model of in-hospital mortality in acute STEMI patients.

Methods: A total of 2,183 inpatients with acute STEMI from January 2002 to December 2011 in China were admitted for development. The first external validation data set came from 7,485 hospitalized patients with acute STEMI from January 2012 to August 2019 in China. The second external validation data set came from 129,042 hospitalized patients with acute STEMI from January 2016 to December 2018 in the United States. We used two-class multiple logistic regression analysis to analyze the risk factors of in-hospital mortality in the development data set. We developed a diagnostic model of in-hospital mortality and constructed a nomogram. We evaluated the predictive performance of the diagnostic model in the two validation data set by examining the measures of discrimination, calibration, and decision curve analysis (DCA).

Results: In the development data set, 61 of the 2,183 participants (2.8%) experienced in-hospital mortality. The strongest predictors of in-hospital mortality were advanced age and cardiogenic

shock. Logistic regression analysis showed the difference between the two groups with and without in-hospital mortality in age (odds ratio [OR] 1.0755, 95% CI 1.046016-1.105814; *P* <.001), and cardiogenic shock (OR 16.48628, 95% CI 9.435111-28.80702; *P* <.001). We had developed a diagnostic model of in-hospital mortality. The area under the receiver operating characteristic curve (AUC) was 0.8977 (SD 0.0198 , 95% CI 0.85894 - 0.93636). We constructed a nomogram based on age and cardiogenic shock. In-hospital mortality occurred in 127 of 7,485 participants (1.7%) in the first validation data set. The AUC was 0.9179(SD 0.0134 , 95% CI 0.89158-0.94424).In-hospital mortality occurred in 14,064 of 129,042 participants (10.9%) in the second validation data set. The AUC was 0.7679(SD 0.0023 , 95% CI 0.76346-0.77228) .

Conclusion: The strongest predictors of in-hospital mortality were advanced age and cardiogenic shock**.** We had developed and externally validated a diagnostic model of in-hospital mortality in acute STEMI patients. It was found that the discrimination, calibration and DCA of this model were satisfactory.

Introduction

Coronary heart disease is still the leading cause of death. [1]In the United States, an estimated 605,000 acute myocardial infarction (AMI) events occur each year.[1] In Europe, the in-hospital mortality of patients with ST-segment elevation myocardial infarction (STEMI) is between 4% and 12%. [2]Preventing in-hospital mortality is a crucial step. A tool is needed to help early detection of patients with increased in-hospital mortality. The Global Registration Risk Score for Acute Coronary Events (GRACE)was designed for emergency clinical situations and can be accessed via mobile

devices, so it enjoied a high reputation among users. Myocardial infarction thrombolysis (TIMI) risk score can predict the clinical manifestations of 30-day mortality in patients with fibrinolytic-eligible STEMI.[3]But the risk scores of GRACE [4-7] and TIMI[3] are too complicated to be easily applied. The purpose of our research was to develop and externally verify a diagnostic model of in-hospital mortality in acute STEMI patients.

Methods

We followed Li's method. 2020. [8]

The derivative cohort was 2,183 patients with acute STEMI from January 2002 to December 2011 in Beijing Anzhen Hospital, Capital Medical University, China. The first external validation data set came from 7,485 hospitalized patients with acute STEMI from January 2012 to August 2019 in Beijing Anzhen Hospital, Capital Medical University, China. The second external validation data set came from 129,042 hospitalized patients with acute STEMI from January 2016 to December 2018 in the United States. Data from the National (Nationwide) Inpatient Sample (NIS) were used for this study. Inclusion criteria: 1. all those STEMI patients who are hospitalized; 2. all those STEMI patients over 18 years of age. Exclusion criteria: none. We established the diagnosis of AMI and STEMI based on the fourth general definition of myocardial infarction.[9]It was a retrospective analysis and informed consent was waived by Ethics Committee of Beijing Anzhen Hospital Capital Medical University. Outcome of interest was in-hospital mortality. All in-hospital mortality was defined as cardiogenic or non-cardiogenic death during hospitalization. The presence or absence of in-hospital mortality was decided blinded to the predictor variables and based on the medical record.

We selected 12 predictors based on clinical relevance and baseline descriptive statistics.Since the purpose of this work was to develop a diagnostic model that could be calculated at the first medical contact, we were only interested in clinical variables that were easily available in the emergency department. The potential candidate variables were age, sex, cardiogenic shock, atrioventricular(AV) block, atrial fibrillation(AF), and medical history such as hypertension, diabetes, myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass grafting(CABG), cerebrovascular disease, chronic kidney disease(CKD). All of them based on the

medical record and blinded to the predictor variables. AF was defined as all type of AF during hospitalization. AV block was defined as all type of AV block during hospitalization.

Some people suggested that each candidate variable had at least 10 events for model derivation and at least 100 events for validation studies. [10]Our sample and the number of deaths in the hospital exceeded all methods of determining the sample size, so it was expected to provide a very reliable estimate. [10]

To ensure reliability of data, we excluded patient who had missing information on predictors. We kept all continuous data as continuous and retained on the original scale. We used univariable and multivariable logistic regression models to identify the correlates of in-hospital mortality. We entered all variables of Tables 1 into the univariable logistic regression. Based on the variables significantly generated by univariate logistic regression, we constructed a multivariate logistic regression model using the backward variable selection method. We use Akanke Information Criteria (AIC) and Bayes Information Criteria (BIC) to select predictors. It considered model fitting and penalizes the estimated number of parameters, which was equivalent to using α = .157. [10]Internal validity was evaluated by means of bootstrap technigues.[10]We assessed the predictive performance of the diagnostic model in the validation data sets by examining measures of discrimination, calibration and decision curve analysis (DCA).[8,10]Discrimination was the ability of the diagnostic model to differentiate between patient who with and without in-hospital mortality. This measure was quantified by calculating the area under the receiver operating characteristic (ROC) curve (AUC).[10]Calibration refers to how closely the predicted in-hospital mortality agreeed with the observed in-hospital mortality. The Brier score was an aggregate measure of disagreement between the observed outcome and a prediction—the average squared error difference.We used DCA to describe and compare the clinical effects of diagnostic model.[10]We performed statistical analyses with STATA version 15.1 (StataCorp), R version 4.0.0(R Project) , and the RMS package developed by Harrell et al.[11]

Results

The study was approved by the ethics committee on October 25, 2019. Data collection started on

November 6 , 2019. As of submission of the manuscript, 138,710 people had been recruited for

the study.

A flow diagram of the study was presented in Figure 1. In the development data set, 61 out of

2,183 hospitalized patients (2.8%) experienced in-hospital mortality. The patients' baseline

characteristics were shown in Table 1. Six variables (age ,sex , history of myocardial infarction,

history of CABG, cardiogenic shock, and AF)were significant differences in the two groups of

patient($P< . 157$). After application of backward variable selection method, AIC and BIC, age and

cardiogenic shock remained as significant independent predictors of in-hospital mortality. These

results were shown in Table 2 and Table 3.

Table 1. Demographic and clinical characteristics of patient with and

without in-hospital mortality in the development data sets

Characteristic [lower limit, upper limit]	Total (n=2183)	In-hospital deaths (n =61)	In hospital survivors (n=2122)	P value
Age(year,x±s)[21,91]	60±13	71±12	59±12	<.001
Male sex n(%)	1688(77.3)	36(59)	1652(77.9)	.001
Medical history n (%)				
Hypertension	1243(56.9)	36(59)	1207(56.9)	.740
Diabetes	674(30.9)	19(31.1)	655(30.9)	.963
Myocardial infarction	231(10.6)	13(21.3)	218(10.3)	.007
PCI[a]	159(7.3)	3(4.9)	156(7.4)	.474
CABG[b]	17(0.8)	2 (1.6)	15(0.7)	.041

CKD[c]	48(2.2)	2(3.3)	46(2.2)	.563
HCD[d]	172(7.9)	5(8.2)	167(7.9)	.926
Cardiogenic shock n (%)	161(7.4)	36(59)	125(5.9)	<.001
AF[e] n(%)	161(18)	11(18)	113 (5.3)	<.001
AVB[f] n(%)	104(6.6)	4(6.6)	100(4.7)	.507

[a]PCI: percutaneous coronary intervention. [b]CABG: coronary artery bypass graft. [c]CKD: chronic kidney disease.
[d]HCD: history of cerebrovascular disease.[e]AF: atrial fibrillation.[f]AVB: atrioventricular block.

Table 2. Predictor of in-hospital mortality obtained from multivariable logistic regression models(odds ratio)in the development data sets

In-hospital mortality	Odds ratio	Standard error	Z	Pr>| Z |	95% CI
Age	1.0755	.0152531	5.13	<.001	1.046016~1.105814
Cardiogenic shock	16.48628	4.694391	9.84	<.001	9.435111~28.80702
Constant	.0001157	.0001155	-9.08	<.001	.0000164 ~.0008185

Table 3. Predictor of in-hospital mortality obtained from multivariable logistic regression models(coefficients)in the development data sets

In-hospital mortality	Coefficient	Standard error	Z	Pr>| Z |	95% CI
Age	.0727853	.0141823	5.13	<.001	.0449886~.1005821
Cardiogenic shock	2.802528	.2847453	9.84	<.001	2.244438~3.360619
Constant	-9.064425	.9981449	-9.08	<.001	-11.02075~-7.108097

According to the above risk factors, we can calculate the predicted probability of in-hospital mortality using the following formula:$P= 1/(1+\exp(-(-9.064425+.0727853\times Age(year)+2.802528\times CS)))$, where CS was cardiogenic shock(0 = No, 1 = Yes).The ROC curve was drawn(Figure A2).AUC was 0.8977 (SD 0.0198 , 95% CI 0.85894 - 0.93636).We constructed the nomogram(Figure 2) using the development database based on the two prognostic markers: age and cardiogenic shock. To use the nomogram, the patient's age was found on the AGE axis, and a straight line was then drawn upward to the Points axis to determine how many points toward progression the patient receives for their age. The steps were repeated for the other axes, with a straight line drawn upward each time toward the points axis. The points received for each predictor are summed, and the sum was found on the total points axis. A straight line was drawn down to the Risk of In-Hospital Mortality axis to find the patient's probability of in-hospital mortality.The results of internal validation showed that the model's prediction discrimination rate (c index is 0.8977) was not "over-optimism", and the c index remains at 0.89925 when using the bootstrap technique.

In the first validation data set, 127 out of 7,485 hospitalized patients (1.7%) experienced in-hospital mortality. The baseline characteristics of the patients were shown in Table 4.

Table 4. Demographic and clinical characteristics of patient with and without in-hospital mortality in the first validation data sets

Characteristic [lower limit, upper limit]	Total (n =7485)	In-hospital mortalitys (n =127)	In hospital survivors (n=7358)	P value
Age (year, x±s) [21,91]	59±12	70±12	59±12	<.001
Male sex n (%)	6033(65.4)	83(65.4)	5950(80.9)	<.001
Medical history, n (%)				
Hypertension	4231(67.7)	86(67.7)	4145(56.3)	.011

Characteristic	Total	In-hospital mortality	In hospital survivors	P value
Diabetes	2254(35.4)	45(35.4)	2209(30)	.189
Myocardial infarction	563(12.6)	16(12.6)	547(7.4)	.031
PCI[a]	627(9.4)	12(9.4)	615(8.4)	.66
CABG[b]	61(1.6)	2(1.6)	59(0.8)	.346
CKD[c]	179(2.4)	9(7.1)	170(2.3)	.001
HCD[d]	516(6.9)	18(14.2)	498(6.8)	.001
Cardiogenic shock n (%)	453(5)	88(69.3)	365(5)	<.001
AF[e] n(%)	364(4.6)	24(18.9)	340(4.6)	<.001
AVB[f] n(%)	187(2.1)	14(11)	173(2.4)	<.001

[a]PCI: percutaneous coronary intervention. [b]CABG: coronary artery bypass graft. [c]CKD: chronic kidney disease.
[d]HCD: history of cerebrovascular disease.[e]AF: atrial fibrillation.[f]AVB: atrioventricular block.

We can calculate the predicted probability of in-hospital mortality using the following formula: $P =1/(1+\exp(-(-9.064425+.0727853\times Age(year)+2.802528\times CS)))$, where CS was cardiogenic shock(0 = No, 1 = Yes).We drew the ROC curve(Figure 4).AUC was 0.9179(SD 0.0134 , 95% CI 0.89158-0.94424). The Brier score was 0.0142(<.25).Figure5 shows the DCA of the validation data set.

In the second validation data set, 14,064 out of 129,042 hospitalized patients (10.9%) experienced in-hospital mortality. The baseline characteristics of the patients were shown in 5.

Table 5. Demographic and clinical characteristics of patient with and without in-hospital mortality in the second validation data sets

Characteristic [lower limit, upper limit]	Total (n =129,042)	In-hospital mortalitys (n = 14,064)	In hospital survivors (n= 114,978)	P value
Age (year, x±s) [21,90]	64±13	71±13	63±13	<.001
Cardiogenic shock n (%)	17,032 (13.2)	6,115(43.5)	10,917 (9.5)	<.001

We drew the ROC curve(Figure 6). AUC was 0.7679(SD 0.0023 , 95% CI 0.76346-0.77228) . The Brier score was 0.0899(<.25) . Figure 7 shows the DCA of the validation data set .

Discussion

The mortality in STEMI patients was affected by many factors, including advanced age and Killip class, and so on. [12] In this study, we investigated the predisposing factors of in-hospital mortality in patients with acute STEMI. A frequency of in-hospital mortality was 2.8% (61/2183). Age and cardiogenic shock were significant independent predictors of in-hospital mortality.We assessed the predictive performance of the diagnostic model in the validation data sets by examining measures of discrimination, calibration and DCA.AUC was 0.9179(SD 0.0134 , 95% CI 0.89158-0.94424)in the first validation data sets and the Brier score was 0.0142(<.25). AUC was 0.7679(SD 0.0023 , 95% CI 0.76346-0.77228) in the second validation data sets and the Brier score was 0.0899(<.25) . The discrimination, calibration, and DCA results were found to be satisfactory.

Cardiogenic shock has been associated with increased risk of in-hospital mortality.[13-22] Cardiogenic shock is common and highly morbid. Acute myocardial infarction is the most common cause of cardiogenic shock.[28] Cardiogenic shock is a clinical condition defined as the inability of the heart, generally as a result of impairment of its pumping function,to deliver an adequate amount of blood to the tissues to meet resting metabolic demands.[13,23, 24]Mounting evidence mandates a more nuanced view of cardiogenic shock that factors in the complex interactions between the ventricles and the systemic or pulmonary vasculature, the interdependence between the left and right ventricles, and the molecular and inflammatory milieu that often accompanies cardiogenic shock.[28]

Granger CB et al.observed that age, Killip class, systolic blood pressure, ST-segment deviation, cardiac arrest during presentation, serum creatinine level, positive initial cardiac enzyme findings, and heart rate were independent predictors of in-hospital mortality among 11,389 patients in the GRACE.[4] Karen S. Pieper et al. generated the updated GRACE risk model and a nomogram.[6]The GRACE risk model has since been upgraded[7]and simplified. [37]TIMI risk score predicting 30-day mortality at presentation of fibrinolytic-eligible patients with STEMI. [3] C-ACS[38]was simple four-variable scores that have been developed to enable risk stratification at first medical contact. Acute coronary treatment and intervention outcomes network (ACTION) score[39]used 65,668 patients to develop and 16,336 patients to validate a model to predict in-hospital mortality . This was a form of internal validation because their cohorts were randomly created .[10]

So far, clinicians and researchers usually use GRACE or TIMI scores to guide treatment decisions. Our diagnostic model of in-hospital mortality builded upon these studies in several ways. It was an absolute value. It can be easily calculated at patient presentation. It includes only baseline factors, namely age and cardiogenic shock. The nomogram was easier to use. Finally, the c statistic of the model at 0.8977 in the derivation , 0.9179 in the first validation cohort, and 0.7679 in the second validation cohort were strong.

The present analysis had few limitations. Some patient were enrolled >10 years ago thus their treatment may not conform to current standards and techniques.

Conclusion

The strongest predictors of in-hospital mortality were advanced age and cardiogenic shock.We developed and externally validated a diagnostic model of in-hospital mortality in patient with acute STEMI . It was found that the discrimination, calibration and DCA of this model were satisfactory.

List of abbreviations.

AF =atrial fibrillation; AIC =Akanke information criterion; AMI=acute myocardial infarction; AUC=area under the receiver operating characteristic curve;AVB =atrioventricular block; BIC =Bayesian information criterion; CABG =coronary artery bypass grafting; CI=confidence interval; CKD =chronic kidney disease; CS = cardiogenic shock;DCA = decision curve analysis; PCI= percutaneous coronary intervention; MI= myocardial infarction; ROC=receiver operating characteristic; STEMI=ST elevation myocardial infarction; NIS=National (Nationwide) Inpatient Sample.

Declarations

Acknowledgments

Not applicable.

Funding Sources

This research received no external funding.

Disclosure

None.

Statement of Ethics

Ethic committee approved the study. Approved No. of ethic committee: 2019039X.

Name of the ethic committee:Ethics committee of Beijing Anzhen Hospital Capital Medical University. We registered this study with WHO International Clinical Trials Registry Platform (ICTRP) (registration number: ChiCTR1900027129; registered date: 1 November 2019).

http://www.chictr.org.cn/edit.aspx?pid=44888&htm=4.It was a retrospective analysis and informed consent was waived by Ethics Committee of Beijing Anzhen Hospital Capital Medical University.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was not conducted with animals.

Consent to publish

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Supplementary materials

The data are demographic, and clinical characteristics of patients with acute STEMI. AGE= age; ALLAF =atrial fibrillation; AVB =atrioventricular block; CABG =history of coronary artery bypass grafting ; CKD= history of chronic kidney disease; DIE= in-hospital mortality; DM= history of diabetes; HBP = history of hypertension; HCD= history of cerebrovascular disease; HPCI=history of percutaneous coronary intervention; CS = Cardiogenic shock; OMI=history of myocardial infarction; PCI=underwent PCI during hospitalization; S = sex. Data from the National (Nationwide) Inpatient Sample (NIS) data from January 2016 to December 2018 in the United States were used for this study.https://www.hcup-us.ahrq.gov/.

Author Contributions

YL contributed to the generation of the study data, analyzed and interpreted the study data,

drafted the manuscript, and revised the manuscript. YL was responsible for the overall content as guarantor. The author read and approved the final manuscript.

Figure 1. Flow diagrams.

Figure 2. Receiver-operating characteristics curve in identifying patients with in-hospital mortality in the

development dataset.

Figure 3. Nomogram for predicting in-hospital mortality in patient with acute STEMI AGE=Age(year); CS =

Cardiogenic shock(0=No, 1=Yes).

Figure 4. Receiver-operating characteristics curve in identifying patients with in-hospital mortality

in the first validation data sets .

Figure 5. Decision curve analysis in the first validation data sets.

Figure 6. Receiver-operating characteristics curve in identifying patients with in-hospital mortality

in the second validation data sets .

Figure 7. Decision curve analysis in the second validation data sets.

References

[1]   Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019. 139(10): e56-e528.

[2]   Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J. 2014. 35(29): 1957-70.

[3]   Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000. 102(17): 2031-7.

[4]   Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003. 163(19): 2345-53.

[5]   Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004. 291(22): 2727-33.

[6]   Pieper KS, Gore JM, FitzGerald G, et al. Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events. Am Heart J. 2009. 157(6): 1097-105.

[7]   Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014. 4(2): e004425.

[8]   Li Y. Diagnostic Model for In-Hospital Bleeding in Patients with Acute ST-Segment Elevation Myocardial Infarction: Algorithm Development and Validation. JMIR Med Inform. 2020. 8(8): e20974.

[9]   Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018. 72(18): 2231-2264.

[10] Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015. 162(1): W1-73.

[11] Harrell FE Jr, Margolis PA, Gove S, et al. Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological agents of Pneumonia, Sepsis and Meningitis in Young Infants. WHO/ARI Young Infant Multicentre Study Group. Stat Med. 1998. 17(8): 909-44.

[12] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018. 39(2): 119-177.

[13] Zeymer U, Bueno H, Granger CB, et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2020. 9(2): 183-197.

[14] Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967. 20(4): 457-64.

[15] Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J. 1998. 135(5 Pt 1): 786-96.

[16] Wu AH, Parsons L, Every NR, Bates ER, Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002. 40(8): 1389-94.

[17] Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004. 109(4): 494-9.

[18] De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation. 2004. 109(22): 2737-43.

[19] Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005. 45(9): 1397-405.

[20] DeGeare VS, Boura JA, Grines LL, O'Neill WW, Grines CL. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2001. 87(9): 1035-8.

[21] El-Menyar A, Zubaid M, AlMahmeed W, et al. Killip classification in patients with acute coronary syndrome: insight from a multicenter registry. Am J Emerg Med. 2012. 30(1): 97-103.

[22] Taguchi E, Konami Y, Inoue M, et al. Impact of Killip classification on acute myocardial infarction: data from the SAIKUMA registry. Heart Vessels. 2017. 32(12): 1439-1447.

[23] van Diepen S, Katz JN, Albert NM, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017. 136(16): e232-e268.

[24] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed). 2016. 69(12): 1167.

[25] Cooper LB, Mentz RJ, Stevens SR, et al. Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow. J Card Fail. 2016. 22(3): 182-9.

[26] Tsagalou EP, Kanakakis J, Anastasiou-Nana MI, et al. Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance. Acute Card Care. 2009. 11(2): 99-106.

[27] Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004. 44(2): 340-8.

[28] Brener MI, Rosenblum HR, Burkhoff D. Pathophysiology and Advanced Hemodynamic Assessment of Cardiogenic Shock.

Methodist Debakey Cardiovasc J. 2020. 16(1): 7-15.

[29]   Akiyama K, Suzuki H, Grant P, Bing RJ. Oxidation products of nitric oxide, NO2 and NO3, in plasma after experimental myocardial infarction. J Mol Cell Cardiol. 1997. 29(1): 1-9.

[30]   Wildhirt SM, Dudek RR, Suzuki H, Bing RJ. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Int J Cardiol. 1995. 50(3): 253-61.

[31]   Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002. 53(1): 31-47.

[32]   Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004. 94(12): 1543-53.

[33]   Toleva O, Ibrahim Q, Brass N, Sookram S, Welsh R. Treatment choices in elderly patients with ST: elevation myocardial infarction-insights from the Vital Heart Response registry. Open Heart. 2015. 2(1): e000235.

[34]   Malkin CJ, Prakash R, Chew DP. The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the ACACIA registry. BMJ Open. 2012. 2(1): e000540.

[35]   Alabas OA, Allan V, McLenachan JM, Feltbower R, Gale CP. Age-dependent improvements in survival after hospitalisation with acute myocardial infarction: an analysis of the Myocardial Ischemia National Audit Project (MINAP). Age Ageing. 2014;43(6):779-85 .

[36]   Brieger D, Eagle KA, Goodman SG, et al. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest. 2004. 126(2): 461-9.

[37]   Huang W, FitzGerald G, Goldberg RJ, et al. Performance of the GRACE Risk Score 2.0 Simplified Algorithm for Predicting 1-Year Death After Hospitalization for an Acute Coronary Syndrome in a Contemporary Multiracial Cohort. Am J Cardiol. 2016. 118(8): 1105-1110.

[38]   Huynh T, Kouz S, Yan AT, et al. Canada Acute Coronary Syndrome Risk Score: a new risk score for early prognostication in acute coronary syndromes. Am Heart J. 2013. 166(1): 58-63.

[39]   Chin CT, Chen AY, Wang TY, et al. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011. 161(1): 113-122.e2.